Cost-effectiveness of bisphosphonates for prevention of fracture related to glucocorticoid-induced osteoporosis in Malaysia.
Nurul-Ain Mohd-TahirParaidathathu ThomasMohd Shahrir Mohamed SaidMohd Makmor-BakryShu-Chuen LiPublished in: International journal of rheumatic diseases (2017)
Fracture risk factors of age, previous fracture, rheumatoid arthritis and secondary osteoporosis may modify the cost-effectiveness outcomes of bisphosphonates. Bisphosphonates would be considered cost-effective in patients more than 60 years old as compared to calcium/vitamin D treatments. Further evaluation of the impact of fracture risk factors in larger populations would provide more precise information to better assist rational and economical use of anti-osteoporosis treatment in GIOP patients.
Keyphrases
- risk factors
- end stage renal disease
- rheumatoid arthritis
- newly diagnosed
- postmenopausal women
- chronic kidney disease
- ejection fraction
- bone mineral density
- peritoneal dialysis
- healthcare
- metabolic syndrome
- hip fracture
- patient reported outcomes
- type diabetes
- skeletal muscle
- systemic sclerosis
- systemic lupus erythematosus
- diabetic rats
- endothelial cells
- high glucose
- ankylosing spondylitis
- patient reported
- social media
- glycemic control